|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/25/20 NTN Buzztime Inc. S-4/A 207:22M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: S-4/A Pre-Effective Amendment to Registration Statement HTML 4.43M
- Securities for a Merger
2: EX-5.1 Opinion of Counsel re: Legality HTML 58K
3: EX-10.16(A) Material Contract HTML 72K
4: EX-10.16(B) Material Contract HTML 74K
5: EX-10.17(A) Material Contract HTML 72K
6: EX-10.17(B) Material Contract HTML 58K
7: EX-10.17(C) Material Contract HTML 74K
8: EX-10.17(D) Material Contract HTML 66K
9: EX-10.18 Material Contract HTML 74K
10: EX-10.19(A) Material Contract HTML 235K
11: EX-10.19(B) Material Contract HTML 61K
12: EX-10.19(C) Material Contract HTML 72K
13: EX-10.20 Material Contract HTML 126K
14: EX-10.21 Material Contract HTML 68K
15: EX-10.22 Material Contract HTML 71K
16: EX-10.23(A) Material Contract HTML 284K
17: EX-10.23(B) Material Contract HTML 63K
18: EX-10.23(C) Material Contract HTML 66K
19: EX-10.23(D) Material Contract HTML 101K
20: EX-10.24(A) Material Contract HTML 219K
21: EX-10.24(B) Material Contract HTML 77K
22: EX-10.24(C) Material Contract HTML 66K
23: EX-23.4 Consent of Expert or Counsel HTML 54K
24: EX-23.5 Consent of Expert or Counsel HTML 54K
25: EX-99.1 Miscellaneous Exhibit HTML 53K
27: EX-99.10 Miscellaneous Exhibit HTML 54K
28: EX-99.11 Miscellaneous Exhibit HTML 54K
29: EX-99.12 Miscellaneous Exhibit HTML 54K
30: EX-99.13 Miscellaneous Exhibit HTML 54K
26: EX-99.9 Miscellaneous Exhibit HTML 54K
37: R1 Document and Entity Information HTML 68K
38: R2 Condensed Consolidated Balance Sheets HTML 171K
39: R3 Condensed Consolidated Balance Sheets HTML 83K
(Parenthetical)
40: R4 Condensed Consolidated Statements of Operations HTML 134K
and Comprehensive Loss (Unaudited)
41: R5 Condensed Consolidated Statements of Operations HTML 56K
and Comprehensive Loss (Unaudited) (Parenthetical)
42: R6 Condensed Consolidated Statements of Shareholders' HTML 122K
Equity (Unaudited)
43: R7 Condensed Consolidated Statements of Cash Flows HTML 195K
(Unaudited)
44: R8 Condensed Balance Sheets (Brooklyn HTML 144K
ImmunoTherapeutics, LLC)
45: R9 Condensed Statements of Operations (Unaudited) HTML 103K
(Brooklyn ImmunoTherapeutics, LLC)
46: R10 Condensed Statements of Changes in Members' Equity HTML 149K
(Brooklyn ImmunoTherapeutics, LLC)
47: R11 Condensed Statements of Cash Flows (Brooklyn HTML 265K
ImmunoTherapeutics, LLC)
48: R12 Basis of Presentation HTML 62K
49: R13 Organization of Company HTML 61K
50: R14 Merger Agreement and Asset Purchase Agreement HTML 60K
51: R15 Covid-19-Update HTML 59K
52: R16 Going Concern Uncertainty HTML 66K
53: R17 Summary of Significant Accounting Policies And HTML 131K
Estimates
54: R18 Restricted Cash HTML 59K
55: R19 Fixed Assets, Net HTML 65K
56: R20 Fair Value of Financial Instruments HTML 62K
57: R21 Accrued Compensation HTML 61K
58: R22 Concentrations of Risk HTML 60K
59: R23 Revenue Recognition HTML 112K
60: R24 Basic and Diluted Earnings Per Common Share HTML 59K
61: R25 Shareholders' Equity HTML 116K
62: R26 Income Taxes HTML 87K
63: R27 Debt HTML 66K
64: R28 Long-term Debt HTML 59K
65: R29 Leases HTML 110K
66: R30 Commitments and Contingencies HTML 58K
67: R31 Disposition of Site Equipment to Be Installed and HTML 61K
Fixed Assets
68: R32 Software Development Costs HTML 60K
69: R33 Goodwill HTML 66K
70: R34 Accumulated Other Comprehensive Income HTML 59K
71: R35 Recent Accounting Pronouncements HTML 65K
72: R36 Retirement Savings Plan HTML 57K
73: R37 Subsequent Events HTML 65K
74: R38 Organization and Description of Business HTML 65K
Operations (Brooklyn ImmunoTherapeutics, LLC)
75: R39 Description of Business (Brooklyn HTML 57K
ImmunoTherapeutics, LLC) (10-K)
76: R40 Going Concern (Brooklyn ImmunoTherapeutics, LLC) HTML 72K
77: R41 Basis of Presentation and Summary of Significant HTML 72K
Accounting Policies (Brooklyn ImmunoTherapeutics,
LLC)
78: R42 Summary of Significant Accounting Policies HTML 150K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
79: R43 Merger With NTN Buzztime, Inc (Brooklyn HTML 59K
ImmunoTherapeutics, LLC)
80: R44 Fair Value of Financial Instruments (Brooklyn HTML 74K
ImmunoTherapeutics, LLC)
81: R45 Business Combination (Brooklyn ImmunoTherapeutics, HTML 61K
LLC) (10-K)
82: R46 Property and Equipment (Brooklyn HTML 76K
ImmunoTherapeutics, LLC)
83: R47 Goodwill and in Process Research and Development HTML 56K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
84: R48 Security Deposits and Other Assets (Brooklyn HTML 58K
ImmunoTherapeutics, LLC)
85: R49 Accrued Expenses (Brooklyn ImmunoTherapeutics, HTML 65K
LLC)
86: R50 Investor Deposits (Brooklyn ImmunoTherapeutics, HTML 55K
LLC) (10-K)
87: R51 Loans Payable (Brooklyn ImmunoTherapeutics, LLC) HTML 68K
88: R52 Loans Payable and Loans Payable to Related Parties HTML 59K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
89: R53 Commitments and Contingencies (Brooklyn HTML 82K
ImmunoTherapeutics, LLC)
90: R54 Stock-Based Compensation (Brooklyn HTML 62K
ImmunoTherapeutics, LLC)
91: R55 Members' Equity (Brooklyn ImmunoTherapeutics, LLC) HTML 57K
92: R56 Stockholders' Deficiency and Members' Equity HTML 75K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
93: R57 Income Tax (Brooklyn ImmunoTherapeutics, LLC) HTML 101K
(10-K)
94: R58 Subsequent Events (Brooklyn ImmunoTherapeutics, HTML 72K
LLC)
95: R59 Summary of Significant Accounting Policies And HTML 180K
Estimates (Policies)
96: R60 Basis of Presentation and Summary of Significant HTML 96K
Accounting Policies (Policies) (Brooklyn
ImmunoTherapeutics, LLC)
97: R61 Summary of Significant Accounting Policies HTML 129K
(Policies) (Brooklyn ImmunoTherapeutics, LLC)
(10-K)
98: R62 Summary of Significant Accounting Policies And HTML 118K
Estimates (Tables)
99: R63 Fixed Assets, Net (Tables) HTML 66K
100: R64 Accrued Compensation (Tables) HTML 59K
101: R65 Revenue Recognition (Tables) HTML 118K
102: R66 Shareholders' Equity (Tables) HTML 100K
103: R67 Income Taxes (Tables) HTML 84K
104: R68 Leases (Tables) HTML 95K
105: R69 Goodwill (Tables) HTML 63K
106: R70 Business Combination (Tables) (Brooklyn HTML 60K
ImmunoTherapeutics, LLC) (10-K)
107: R71 Fair Value of Financial Instruments (Tables) HTML 63K
(Brooklyn ImmunoTherapeutics, LLC)
108: R72 Property and Equipment (Tables) (Brooklyn HTML 70K
ImmunoTherapeutics, LLC)
109: R73 Accrued Expenses (Tables) (Brooklyn HTML 64K
ImmunoTherapeutics, LLC)
110: R74 Commitments and Contingencies (Tables) (Brooklyn HTML 59K
ImmunoTherapeutics, LLC) (10-K)
111: R75 Stockholders' Deficiency and Members' Equity HTML 83K
(Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K)
112: R76 Income Tax (Tables) (Brooklyn ImmunoTherapeutics, HTML 89K
LLC) (10-K)
113: R77 Basis of Presentation (Details Narrative) HTML 55K
114: R78 Organization of Company (Details Narrative) (10-K) HTML 61K
115: R79 Merger Agreement and Asset Purchase Agreement HTML 74K
(Details Narrative)
116: R80 Covid-19-Update (Details Narrative) HTML 60K
117: R81 Going Concern Uncertainty (Details Narrative) HTML 97K
118: R82 Going Concern Uncertainty (Details Narrative) HTML 78K
(10-K)
119: R83 Summary of Significant Accounting Policies and HTML 199K
Estimates (Details Narrative) (10-K)
120: R84 Summary of Significant Accounting Policies and HTML 78K
Estimates - Schedule of Disaggregation of Revenues
(Details) (10-K)
121: R85 Summary of Significant Accounting Policies and HTML 61K
Estimates - Schedule of Revenues Geographic
Breakdown (Details) (10-K)
122: R86 Summary of Significant Accounting Policies and HTML 65K
Estimates - Schedule of Contract Liabilities
(Details) (10-K)
123: R87 Summary of Significant Accounting Policies and HTML 63K
Estimates - Schedule of Unamortized Installation
Cost and Sales Commissions (Details) (10-K)
124: R88 Restricted Cash (Details Narrative) HTML 72K
125: R89 Restricted Cash (Details Narrative) (10-K) HTML 75K
126: R90 Fixed Assets, Net (Details Narrative) (10-K) HTML 56K
127: R91 Fixed Assets, Net - Schedule of Property and HTML 70K
Equipment (Details) (10-K)
128: R92 Fixed Assets, Net - Schedule of Asset Geographic HTML 59K
Breakdown (Details) (10-K)
129: R93 Accrued Compensation - Schedule of Accrued HTML 66K
Compensation (Details) (10-K)
130: R94 Concentrations of Risk (Details Narrative) (10-K) HTML 75K
131: R95 Revenue Recognition - (Details Narrative) HTML 62K
132: R96 Revenue Recognition - Schedule of Disaggregates HTML 78K
Material Revenue (Details)
133: R97 Revenue Recognition - Schedule of Revenues HTML 62K
Geographic Breakdown (Details)
134: R98 Revenue Recognition - Schedule of Contract HTML 66K
Liabilities (Details)
135: R99 Revenue Recognition - Schedule of Unamortized HTML 64K
Installation Cost and Sales Commissions (Details)
136: R100 Basic and Diluted Earnings Per Common Share HTML 57K
(Details Narrative)
137: R101 Basic and Diluted Earnings Per Common Share HTML 57K
(Details Narrative) (10-K)
138: R102 Shareholders' Equity (Details Narrative) HTML 102K
139: R103 Shareholders' Equity (Details Narrative) (10-K) HTML 171K
140: R104 Shareholders' Equity - Schedule of Weighted HTML 64K
Average Assumptions (Details)
141: R105 Shareholders' Equity - Schedule of Weighted HTML 64K
Average Assumptions (Details) (10-K)
142: R106 Shareholders' Equity - Schedule of Restricted HTML 58K
Stock and Common Stock Unit Vested (Details)
143: R107 Shareholders' Equity - Summary of Stock Option HTML 104K
Activity (Details) (10-K)
144: R108 Shareholders' Equity - Summary of Restricted Stock HTML 76K
Unit Activity (Details) (10-K)
145: R109 Shareholders' Equity - Summary of Warrant HTML 77K
Activities (Details) (10-K)
146: R110 Income Taxes (Details Narrative) (10-K) HTML 71K
147: R111 Income Taxes - Schedule of Current and Deferred HTML 89K
Income Tax Provision (Benefit) (Details) (10-K)
148: R112 Income Taxes - Schedule of Deferred Tax Assets and HTML 95K
Liabilities (Details) (10-K)
149: R113 Income Taxes - Schedule of Reconciliation of HTML 72K
Expected Income Taxes (Details) (10-K)
150: R114 Debt (Details Narrative) HTML 159K
151: R115 Long-term Debt (Details Narrative) (10-K) HTML 88K
152: R116 Leases (Details Narrative) HTML 122K
153: R117 Leases (Details Narrative) (10-K) HTML 78K
154: R118 Leases - Schedule of Operating Lease Right-of-use HTML 79K
Assets and Liabilities (Details)
155: R119 Leases - Schedule of Operating Lease Right-of-use HTML 74K
Assets and Liabilities (Details) (10-K)
156: R120 Leases - Schedule of Maturities of Operating HTML 74K
Leases (Details) (10-K)
157: R121 Leases - Schedule of Financing Lease Right-of-use HTML 67K
Assets and Liabilities (Details)
158: R122 Leases - Schedule of Financing Lease Right-of-use HTML 66K
Assets and Liabilities (Details) (10-K)
159: R123 Leases - Schedule of Maturities of Financing HTML 64K
Leases (Details)
160: R124 Leases - Schedule of Maturities of Financing HTML 65K
Leases (Details) (10-K)
161: R125 Disposition of Site Equipment to Be Installed and HTML 70K
Fixed Assets (Details Narrative)
162: R126 Software Development Costs (Details Narrative) HTML 62K
163: R127 Goodwill (Details Narrative) HTML 60K
164: R128 Goodwill (Details Narrative) (10-K) HTML 60K
165: R129 Goodwill - Schedule of Goodwill (Details) HTML 63K
166: R130 Goodwill - Schedule of Goodwill (Details) (10-K) HTML 64K
167: R131 Accumulated Other Comprehensive Income (Details HTML 57K
Narrative)
168: R132 Accumulated Other Comprehensive Income (Details HTML 57K
Narrative) (10-K)
169: R133 Retirement Savings Plan (Details Narrative) (10-K) HTML 57K
170: R134 Subsequent Events (Details Narrative) HTML 63K
171: R135 Subsequent Events (Details Narrative) (10-K) HTML 121K
172: R136 Going Conern (Details Narrative) (Brooklyn HTML 68K
ImmunoTherapeutics, LLC)
173: R137 Basis of Presentation and Summary of Significant HTML 62K
Accounting Policies (Details Narrative) (Brooklyn
ImmunoTherapeutics, LLC)
174: R138 Merger With NTN Buzztime, Inc (Details Narrative) HTML 68K
(Brooklyn ImmunoTherapeutics, LLC)
175: R139 Fair Value of Financial Instruments (Details HTML 61K
Narrative) (Brooklyn ImmunoTherapeutics, LLC)
176: R140 Fair Value of Financial Instruments - Schedule of HTML 64K
Fair Value of Liabilities (Details) (Brooklyn
ImmunoTherapeutics, LLC)
177: R141 Property and Equipment (Details Narrative) HTML 56K
(Brooklyn ImmunoTherapeutics, LLC)
178: R142 Property and Equipment - Schedule of Property and HTML 68K
Equipment (Details) (Brooklyn ImmunoTherapeutics,
LLC)
179: R143 Security Deposits and Other Assets (Details HTML 62K
Narrative) (Brooklyn ImmunoTherapeutics, LLC)
180: R144 Accrued Expenses (Details) (Brooklyn HTML 67K
ImmunoTherapeutics, LLC)
181: R145 Loans Payable (Details Narrative) (Brooklyn HTML 59K
ImmunoTherapeutics, LLC)
182: R146 Commitments and Contingencies (Details Narrative) HTML 99K
(Brooklyn ImmunoTherapeutics, LLC)
183: R147 Stock-Based Compensation (Details Narrative) HTML 56K
(Brooklyn ImmunoTherapeutics, LLC)
184: R148 Members' Equity (Details Narrative) (Brooklyn HTML 67K
ImmunoTherapeutics, LLC)
185: R149 Going Conern (Details Narrative) (Brooklyn HTML 86K
ImmunoTherapeutics, LLC) (10-K)
186: R150 Summary of Significant Accounting Policies HTML 72K
(Details Narrative) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
187: R151 Business Combination (Details Narrative) (Brooklyn HTML 63K
ImmunoTherapeutics, LLC) (10-K)
188: R152 Business Combination - Schedule of Purchase Price HTML 83K
for Acquisition (Details) (Brooklyn
ImmunoTherapeutics, LLC) (10-K)
189: R153 Property and Equipment (Details Narative) HTML 63K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
190: R154 Property and Equipment - Schedule of Property and HTML 68K
Equipment (Details) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
191: R155 Goodwill and in Process Research and Development HTML 59K
(Details Narrative) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
192: R156 Security Deposits and Other Assets (Details HTML 65K
Narrative) (Brooklyn ImmunoTherapeutics, LLC)
(10-K)
193: R157 Accrued Expenses (Details) (Brooklyn HTML 70K
ImmunoTherapeutics, LLC) (10K)
194: R158 Investor Deposits (Details Narrative) (Brooklyn HTML 55K
ImmunoTherapeutics, LLC) (10-K)
195: R159 Loans Payable and Loans Payable to Related Parties HTML 101K
(Details Narrative) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
196: R160 Commitments and Contingencies (Details Narrative) HTML 130K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
197: R161 Commitments and Contingencies - Schedule of Future HTML 72K
Commitments of Operating Lease (Details) (Brooklyn
ImmunoTherapeutics, LLC)
198: R162 Stockholders' Deficiency and Members' Equity HTML 167K
(Details Narrative) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
199: R163 Stockholders' Deficiency and Members' Equity - HTML 92K
Schedule of Stock Option Activity (Details)
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
200: R164 Stockholders' Deficiency and Members' Equity - HTML 70K
Schedule of Stock Options Outstanding and
Exercisable (Details) (Brooklyn
ImmunoTherapeutics, LLC) (10-K)
201: R165 Income Tax (Details Narrative) (Brooklyn HTML 61K
ImmunoTherapeutics, LLC) (10-K)
202: R166 Income Tax - Schedule of Income Tax Benefit HTML 84K
(Details) (Brooklyn ImmunoTherapeutics, LLC)
(10-K)
203: R167 Income Tax - Schedule of Deferred Tax Assets and HTML 61K
Liabilities (Details) (Brooklyn
ImmunoTherapeutics, LLC) (10-K)
204: R168 Subsequent Events (Details Narrative) (Brooklyn HTML 61K
ImmunoTherapeutics, LLC) (10-K)
206: XML IDEA XML File -- Filing Summary XML 371K
205: EXCEL IDEA Workbook of Financial Reports XLSX 284K
31: EX-101.INS XBRL Instance -- ntn-20200930 XML 3.47M
33: EX-101.CAL XBRL Calculations -- ntn-20200930_cal XML 459K
34: EX-101.DEF XBRL Definitions -- ntn-20200930_def XML 2.03M
35: EX-101.LAB XBRL Labels -- ntn-20200930_lab XML 2.11M
36: EX-101.PRE XBRL Presentations -- ntn-20200930_pre XML 2.34M
32: EX-101.SCH XBRL Schema -- ntn-20200930 XSD 461K
207: ZIP XBRL Zipped Folder -- 0001493152-20-022484-xbrl Zip 337K
Exhibit 10.23(c)
ASSIGNMENT AND ASSUMPTION OF LEASE
THIS ASSIGNMENT AND ASSUMPTION OF LEASE (this “Agreement”) is made as of November_, 2018, by and between IRX Therapeutics, Inc., a New York corporation (“Assignor”) and Brooklyn Immunotherapeutic LLC, a Delaware limited liability company (“Assignee”),
RECITALS:
A. Pursuant to that certain Lease Agreement, dated September 28, 2015, between BIOBAT, INC„ a Not-for-Profit 501(c)(3) corporation organized under the laws of the State of New York (“Landlord”) and Assignor (“Lease”), Landlord currently leases to Assignor, that certain “Premises” (as more particularly described in the Lease). All initial capitalized terms used herein but not herein defined and defined in the Lease shall have the meaning ascribed to such terms under the Lease,
B. Assignor desires by this Agreement to assign all of its right, title and interest in and to the Lease to Assignee, and Assignee desires to accept such assignment and to agree to perform all of the obligations of the tenant under the Lease from and after the Effective Time (as hereinafter defined), ail upon the terms and conditions hereinafter set forth,
TERMS:
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows;
1. Assignor assigns to Assignee all of its right, title and interest in and to the Lease as of the Effective Time, Assignee hereby accepts the foregoing assignment and assumes and agrees to be bound by and perform all covenants, conditions, obligations and duties of Assignor under the Lease as of the Effective Time. Assignee agrees that it has inspected the Premises and hereby agrees to take the Premises in the condition existing upon the Effective Time.
2. Assignor shall remain obligated to Landlord for the full performance of all covenants, conditions, obligations and duties required of tenant under the Lease and shall not be relieved of any such performance thereunder as a result of this Assignment. However, as of the Effective Time, Assignor shall have no continuing or future possessory rights in and to the Premises and thereafter waives any right it may possess to receive notice from Landlord relative to this Agreement or the Lease.
3. Assignor agrees that any security deposit currently being held by Landlord in the amount of shall be retained by Landlord to mist, the security deposit requirements of “Tenant” under the Lease. Any amount of such security deposit remaining at the expiration of the term of the Lease shall be paid to Assignee after full satisfaction of any amount owed to Landlord,
4. Assignor represents and covenants as follows:
(a) That the Lease is in full force and effect; that Assignor’s interest therein is free and clear of all encumbrances; and that Assignor has fully-performed all covenants and obligations under the Lease and has not done or permitted any acts in violation of the covenants contained in the Lease,
(b) That Assignor has not heretofore assigned, mortgaged or otherwise transferred, amended or encumbered, voluntarily or involuntarily, the Lease or its interest therein or subleased or allowed use or occupancy of the Premises by any other person or entity under a sublease or occupancy agreement remaining in effect.
C:
(c) That Landlord has fully performed all the covenants and obligations on its part to be performed and observed under the Lease; that Landlord has not done or permitted any act or acts in violation of any of the covenants, provisions or terms thereof°, and that there is not now in existence any reason or claim to offset, deduct or decrease any payments due under the Lease,
5. Within thirty (30) days following the Effective Time, Assignor shall pay the Landlord’s attorneys’ fees and costs incurred in connection with the assignment contemplated hereby, Landlord consents to the assignment of the Lease to Assignee only at such time as this Agreement has been executed by all of the parties hereto. Nothing in this Agreement shall be deemed to waive or modify any of the provisions of the Lease, Consent to this Agreement shall not be deemed a consent by Landlord to any further assignment, whether or not Assignee purports to permit the same.
6. Subject to the provisions of Paragraph 5, the provisions of this Agreement shall bind and inure to the benefit of the heirs, representatives, successors and assigns of the parties hereto.
7. Assignee’s address for notices under the Lease shall be the Premises, unless changed in accordance with the Lease.
8. Each individual executing this Agreement on behalf of a partnership, corporation, limited liability company or other entity represents that he or she is duly authorized to execute and deliver this Agreement on behalf of the entity which is a party to this Agreement and agrees to deliver evidence of his or her authority to the other party(ies) upon request.
9. This Agreement may be executed by the parties hereto in separate counterparts, including by facsimile or PDF file, each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute one and the same instrument. Each counterpart may consist of a number of copies hereof each signed by less than all, but together signed by all of, the parties hereto.
10. This Agreement is being entered into in conjunction with the purchase of the Assignor’s business by the Assignee pursuant to a certain Asset Purchase Agreement, by and among Assignor and Assignee (the “Transaction”). The parties to this Agreement agree that this Agreement shall become effective, and shall only become effective, at such time as the closing date of the Transaction (the “Effective Time”). If the Transaction does not close, this Agreement shall automatically become null and void,
C:
| C: 2 |
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.
ASSIGNOR:
IRX THERAPEUTICS, INC. a New York corporation |
ASSIGNEE:
BROOKLYN IMMUNOTHERAPEUTICS, LLC a New York corporation | |||
| By: | /s/ Mark W. Leuchtenberger | By: | /s/ Mark W. Leuchtenberger | |
| Mark W. Leuchtgenberger, CEO | Mark W. Leuchtgenberger, CEO | |||
| 1-14-2019 | 1-14-2019 | |||
C:
| 3 |
Landlord represents that the Lease is in full force and effect and that, to its knowledge, Assignor is not in default of any of its obligations thereunder. Landlord consents to the subject Assignment and Assumption of Lease. Landlord makes no representation regarding Assignor’s compliance with Article XI of the Prime Lease in connection with the subject assignment and assumption.
| LANDLORD: | ||
| BIOBAT, INC. | ||
| a New York Not-for-Profit corporation | ||
| By: | /s/ Eva Cramer | |
| Eva Cramer, President | ||
| (Print Name and Title) | ||
| November 02, 2018 | ||
C:
| 4 |
| This ‘S-4/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/25/20 | CORRESP | ||
| 11/2/18 | ||||
| 9/28/15 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/01/22 Eterna Therapeutics Inc. 10-K/A 12/31/21 92:11M Broadridge Fin’l So… Inc 4/15/22 Eterna Therapeutics Inc. 10-K 12/31/21 95:10M Broadridge Fin’l So… Inc 11/23/21 Eterna Therapeutics Inc. S-1/A 2:185K Broadridge Fin’l So… Inc 11/18/21 Eterna Therapeutics Inc. S-1 4:602K Broadridge Fin’l So… Inc 5/27/21 Eterna Therapeutics Inc. S-1 4:660K Broadridge Fin’l So… Inc 4/30/21 Eterna Therapeutics Inc. S-1 8:2.2M Broadridge Fin’l So… Inc 1/20/21 Eterna Therapeutics Inc. S-4/A 1/19/21 182:20M M2 Compliance LLC/FA 12/22/20 Eterna Therapeutics Inc. S-4/A 183:20M M2 Compliance LLC/FA |